(NASDAQ: TCRX) Tscan Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.01%.
Tscan Therapeutics's earnings in 2026 is -$142,598,000.On average, 8 Wall Street analysts forecast TCRX's earnings for 2026 to be -$51,816,592, with the lowest TCRX earnings forecast at -$82,307,289, and the highest TCRX earnings forecast at -$39,326,359. On average, 7 Wall Street analysts forecast TCRX's earnings for 2027 to be -$49,433,177, with the lowest TCRX earnings forecast at -$60,062,076, and the highest TCRX earnings forecast at -$32,176,112.
In 2028, TCRX is forecast to generate -$52,962,902 in earnings, with the lowest earnings forecast at -$57,281,424 and the highest earnings forecast at -$47,668,314.